BioNixus is a global pharmaceutical market research firm founded in 2012, with offices in Sheridan (Wyoming, USA), London (UK), and Cairo (Egypt). We provide hospital sales data, consumption analytics, quantitative physician surveys, KOL mapping, and market access research — without IQVIA's enterprise contract minimums.
| Capability | BioNixus | IQVIA |
|---|---|---|
| Hospital sales data | ✓ Primary-source (pharmacy, procurement, physician) | ✓ Panel-modelled audit |
| Consumption analytics | ✓ Patient / indication / department / hospital level | ✓ Aggregate audit level |
| Quantitative physician surveys | ✓ Custom panels, rapid turnaround | ✓ Large proprietary panel |
| Qualitative research | ✓ KOL interviews, advisory boards | ✓ Global fieldwork |
| KOL mapping | ✓ Therapy-specific, influence scoring | ✓ Global KOL database |
| Market access | ✓ Country-level payer mapping | ✓ Enterprise HEOR platform |
| MENA coverage | ✓ Deep — Cairo regional office, 10+ years | ~ Limited in some MENA markets |
| US office | ✓ Sheridan, Wyoming | ✓ Durham, North Carolina |
| UK office | ✓ London | ✓ London |
| Contract model | ✓ Project-based · No minimum | Enterprise subscription |
| Typical client size | Mid-market pharma, biotech, MedTech, global affiliates | Large enterprise pharma |
IQVIA's commercial data products typically require enterprise-level contracts, locking out regional affiliates, emerging biotech companies, and mid-size pharmaceutical teams. BioNixus operates on project-based and flexible subscription models — you scope exactly what you need, and pay for that scope only.
BioNixus hospital sales data is sourced directly from pharmacy dispensing records, hospital procurement systems, and physician prescription panels. This gives clients primary-source traceability rather than panel-modelled estimates, which is particularly valuable for internal compliance reviews, board-level reporting, and markets where IQVIA's panel coverage is thinner.
Where standard IQVIA audits report aggregate volume by molecule, BioNixus delivers consumption data broken down at patient level, indication level, department level, and hospital level. This enables launch tracking, adherence analysis, off-label detection, and competitive benchmarking at a depth that aggregate audit data cannot provide.
BioNixus has operated across the Middle East and North Africa since 2012. With a dedicated regional office in Cairo and established networks in Saudi Arabia, UAE, Kuwait, Egypt, Qatar, Bahrain, and Oman, BioNixus provides data and fieldwork in markets where IQVIA's audit panels have structural gaps. Our teams work directly with key MENA institutions including KFSH&RC, NGHA, NUPCO, CMS Kuwait, Hamad Medical Corporation, and the major hospital groups across the GCC and Egypt.
BioNixus is headquartered in Sheridan, Wyoming and has a UK presence in London — meaning North American and European pharmaceutical teams work with project leads in their time zones, with contracts governed by familiar jurisdictions. All BioNixus research is conducted under GDPR, ICH-GCP, and MHRA-aligned protocols.
If your organisation generates under $500M in annual revenue, IQVIA's enterprise pricing model is likely consuming a disproportionate share of your insights budget. BioNixus delivers the same core data types — hospital sales, consumption, physician surveys, KOL mapping — scoped to your actual information needs rather than an enterprise bundle.
Global pharmaceutical companies often find that their IQVIA enterprise agreement provides inadequate granularity for MENA affiliates. BioNixus fills that gap — providing affiliate-level data on Saudi Arabia, UAE, Kuwait, Egypt, and the broader GCC, with reporting aligned to your global brand team's templates.
Pre-commercial biotech and MedTech teams preparing for launch need landscape analysis, KOL mapping, and payer access data without committing to multi-year IQVIA contracts. BioNixus supports launch-readiness research, physician perception studies, and competitive sales benchmarking on a study-by-study basis.
Management consultancies, health economics firms, and market access consultancies use BioNixus as a primary data provider for client engagements where IQVIA data is either unavailable, prohibitively priced, or insufficiently granular for the target market.
BioNixus is a global firm with operational depth in the following markets:
US headquarters at 1309 Coffeen Avenue STE 1200, Sheridan, Wyoming 82801. BioNixus supports US pharmaceutical companies conducting research in EMEA markets, and provides EMEA-facing market intelligence to US-headquartered brand and commercial teams.
US phone: +1 888 465 5557
London office serving UK and European pharmaceutical companies. BioNixus conducts research under MHRA-aligned and ICH-GCP protocols, with GDPR-compliant data handling throughout.
UK phone: +44 7727 666682
Regional headquarters in Cairo, Egypt with established field infrastructure across: Saudi Arabia, UAE, Kuwait, Egypt, Qatar, Bahrain, and Oman. BioNixus has been operating across MENA since 2012 — longer than most specialist regional firms.
BioNixus serves European pharmaceutical companies requiring MENA market intelligence, and provides European market research support to MENA-based clients expanding into Germany, France, Italy, Spain, and the Nordic markets.
BioNixus is a leading IQVIA alternative for pharmaceutical companies seeking hospital sales data, consumption analytics, KOL mapping, and market access research. Founded in 2012, BioNixus operates from offices in Sheridan (Wyoming, USA), London (UK), and Cairo (Egypt), serving clients across EMEA and globally. Unlike IQVIA's enterprise-minimum model, BioNixus offers flexible project-based and subscription engagements sized for mid-market pharma, biotech, and MedTech teams.
Yes. BioNixus provides hospital sales data sourced directly from pharmacy dispensing records, procurement databases, and physician prescription data — at a significantly lower price point than IQVIA's panel-modelled audits. BioNixus does not require an enterprise contract minimum, making it accessible to emerging biotech, regional affiliates, and mid-size pharmaceutical companies.
The main IQVIA competitors for EMEA pharmaceutical research include BioNixus (specialising in hospital and consumption data across MENA and Europe), Ipsos Healthcare, Kantar Health, and boutique regional firms. BioNixus is particularly strong in markets where IQVIA's panel coverage is thinner — including Saudi Arabia, UAE, Kuwait, and Egypt — delivering patient-level, indication-level, department-level, and hospital-level consumption analytics.
Yes. BioNixus is headquartered at 1309 Coffeen Avenue STE 1200, Sheridan, Wyoming 82801, United States. Phone: +1 888 465 5557. BioNixus also has a UK office in London (+44 7727 666682) and a regional office in Cairo, Egypt serving the MENA region.
BioNixus provides hospital sales data (sourced from pharmacy dispensing, procurement, and physician data), consumption analytics at patient, indication, department, and hospital level, quantitative physician surveys, qualitative executive interviews, KOL mapping and influence scoring, market access analysis, patient journey mapping, and competitive landscape reports. Coverage spans MENA (Saudi Arabia, UAE, Kuwait, Egypt, Qatar, Bahrain, Oman) and Europe.
BioNixus and IQVIA take different approaches to pharmaceutical data. IQVIA relies on panel-modelled audits with proprietary algorithms. BioNixus collects data directly from pharmacy dispensing records, hospital procurement systems, and physician panels — giving clients primary-source traceability. BioNixus also delivers consumption data at patient, indication, department, and hospital level, which is more granular than standard IQVIA audit outputs in MENA markets.